Jump to content

Talk:Indacaterol/glycopyrronium bromide

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Proposed changes

[edit]

Hello, I am a Sunovion employee and would like to help update this Wikipedia entry. There are updates that are needed that I would like to work with you on to ensure it’s updated according to Wikipedia guidelines. I look forward to working with you.

Please add ‘In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugdeliverybusiness.com/sunovion-novartis-ink-licensing-deal-inhaled-copd-drugs/

Also, add ‘In 2017, the FDA approved Lonhala Magnair, a new drug product, to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugs.com/history/lonhala-magnair.html


Thanks for your help Ed at Sunovion (talk) 18:30, 13 December 2019 (UTC)[reply]

Reply 13-DEC-2019

[edit]

  Edit request partially implemented  

  1. Green tickY The claim regarding the commercial rights was added to the article.
  2. Red XN The claim regarding Lonhala Magnair was not added to the article.

Regards,  Spintendo  20:25, 13 December 2019 (UTC)[reply]

Proposed changes

[edit]

Hello, I am a Sunovion employee and would like to help update this Wikipedia page with this edit.

Add ‘In 2017, the FDA approved Lonhala Magnair (glycopyrrolate) Inhalation Solution for the treatment of COPD to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://journals.sagepub.com/doi/full/10.1177/1060028018798753


Thanks for your help Ed at Sunovion (talk) 20:59, 13 December 2019 (UTC)[reply]

Reply 13-DEC-2019

[edit]

  Already declined  

  • This proposal was previously declined. The article does not exist for the promotion of new products.

Regards,  Spintendo  22:10, 13 December 2019 (UTC)[reply]